Characteristics of patients undergoing HLA-identical sibling bone marrow transplantation for myelodysplasia
| Variable . | N evaluable . | N (%) Median (range) . |
|---|---|---|
| No. patients | 452 | |
| Age, median (range), y | 452 | 38 (2-64) |
| Age at transplantation 18 y or older | 452 | 387 (86) |
| Male sex | 452 | 260 (58) |
| FAB subtype | 452 | — |
| RA | — | 124 (27) |
| RARS | — | 16 (4) |
| RAEB | — | 136 (30) |
| RAEB-t | — | 136 (30) |
| CMML | — | 40 (9) |
| Hemoglobin at diagnosis < 10 g/dL | 393 | 243 (62) |
| WBC at diagnosis ≤ 3 × 109/L | 406 | 169 (42) |
| Platelets at diagnosis ≤ 100 × 109/L | 400 | 262 (65) |
| Blasts in bone marrow at diagnosis | 362 | — |
| < 5% | — | 141 (39) |
| 5%-10% | — | 80 (22) |
| 11%-20% | — | 96 (27) |
| 21%-30% | — | 45 (12) |
| Cytogenetics | 364 | — |
| Good | — | 213 (59) |
| Intermediate | — | 111 (30) |
| Poor | — | 40 (11) |
| IPSS score at diagnosis | 281 | — |
| Low | — | 32 (11) |
| Intermediate-1 | — | 128 (46) |
| Intermediate-2 | — | 72 (26) |
| High | — | 49 (17) |
| Hemoglobin before transplantation < 10 g/dL | 409 | 220 (54) |
| WBC before transplantation ≤ 3 × 109/L | 449 | 212 (47) |
| Platelets before transplantation ≤ 100 × 109/L | 416 | 285 (69) |
| Blasts in bone marrow before transplantation | 361 | — |
| < 5% | — | 195 (54) |
| 5%-10% | — | 75 (21) |
| 11%-20% | — | 56 (15) |
| 21%-30% | — | 35 (10) |
| IPSS score before transplantation | 340 | — |
| Low | — | 19 (6) |
| Intermediate-1 | — | 145 (43) |
| Intermediate-2 | — | 96 (28) |
| High | — | 80 (23) |
| Treatment for MDS before transplantation | 133 | 73 (55) |
| Conditioning regimen | 452 | — |
| BuCy | — | 154 (34) |
| BuCy + TLI | — | 6 (1) |
| BuCy + others | — | 77 (17) |
| CyTBI | — | 74 (16) |
| CyTBI + others | — | 113 (25) |
| TBI + others (not Cy) | — | 12 (3) |
| Others | — | 16 (3) |
| Donor-recipient CMV status | 434 | — |
| Negative-negative | — | 109 (25) |
| Positive-negative | — | 38 (9) |
| Negative-positive | — | 81 (19) |
| Positive-positive | — | 206 (47) |
| Time from diagnosis to transplantation, median (range), mos | 451 | 5.7 (1-293) |
| Time from diagnosis to transplantation | 451 | — |
| < 6 mos | — | 234 (52) |
| 6-11 mos | — | 107 (23) |
| 12-23 mos | — | 60 (14) |
| ≥ 24 mos | — | 50 (11) |
| Year of transplantation | 452 | — |
| 1989-1990 | — | 107 (24) |
| 1991-1992 | — | 121 (27) |
| 1993-1994 | — | 126 (28) |
| 1995-1997 | — | 98 (21) |
| GVHD prophylaxis | 452 | — |
| CsA ± others (not MTX) | — | 93 (21) |
| CsA + MTX ± others | — | 286 (63) |
| MTX ± others (not CsA) | — | 8 (2) |
| T-depletion ± others | — | 58 (13) |
| Others/none | — | 7 (1) |
| Variable . | N evaluable . | N (%) Median (range) . |
|---|---|---|
| No. patients | 452 | |
| Age, median (range), y | 452 | 38 (2-64) |
| Age at transplantation 18 y or older | 452 | 387 (86) |
| Male sex | 452 | 260 (58) |
| FAB subtype | 452 | — |
| RA | — | 124 (27) |
| RARS | — | 16 (4) |
| RAEB | — | 136 (30) |
| RAEB-t | — | 136 (30) |
| CMML | — | 40 (9) |
| Hemoglobin at diagnosis < 10 g/dL | 393 | 243 (62) |
| WBC at diagnosis ≤ 3 × 109/L | 406 | 169 (42) |
| Platelets at diagnosis ≤ 100 × 109/L | 400 | 262 (65) |
| Blasts in bone marrow at diagnosis | 362 | — |
| < 5% | — | 141 (39) |
| 5%-10% | — | 80 (22) |
| 11%-20% | — | 96 (27) |
| 21%-30% | — | 45 (12) |
| Cytogenetics | 364 | — |
| Good | — | 213 (59) |
| Intermediate | — | 111 (30) |
| Poor | — | 40 (11) |
| IPSS score at diagnosis | 281 | — |
| Low | — | 32 (11) |
| Intermediate-1 | — | 128 (46) |
| Intermediate-2 | — | 72 (26) |
| High | — | 49 (17) |
| Hemoglobin before transplantation < 10 g/dL | 409 | 220 (54) |
| WBC before transplantation ≤ 3 × 109/L | 449 | 212 (47) |
| Platelets before transplantation ≤ 100 × 109/L | 416 | 285 (69) |
| Blasts in bone marrow before transplantation | 361 | — |
| < 5% | — | 195 (54) |
| 5%-10% | — | 75 (21) |
| 11%-20% | — | 56 (15) |
| 21%-30% | — | 35 (10) |
| IPSS score before transplantation | 340 | — |
| Low | — | 19 (6) |
| Intermediate-1 | — | 145 (43) |
| Intermediate-2 | — | 96 (28) |
| High | — | 80 (23) |
| Treatment for MDS before transplantation | 133 | 73 (55) |
| Conditioning regimen | 452 | — |
| BuCy | — | 154 (34) |
| BuCy + TLI | — | 6 (1) |
| BuCy + others | — | 77 (17) |
| CyTBI | — | 74 (16) |
| CyTBI + others | — | 113 (25) |
| TBI + others (not Cy) | — | 12 (3) |
| Others | — | 16 (3) |
| Donor-recipient CMV status | 434 | — |
| Negative-negative | — | 109 (25) |
| Positive-negative | — | 38 (9) |
| Negative-positive | — | 81 (19) |
| Positive-positive | — | 206 (47) |
| Time from diagnosis to transplantation, median (range), mos | 451 | 5.7 (1-293) |
| Time from diagnosis to transplantation | 451 | — |
| < 6 mos | — | 234 (52) |
| 6-11 mos | — | 107 (23) |
| 12-23 mos | — | 60 (14) |
| ≥ 24 mos | — | 50 (11) |
| Year of transplantation | 452 | — |
| 1989-1990 | — | 107 (24) |
| 1991-1992 | — | 121 (27) |
| 1993-1994 | — | 126 (28) |
| 1995-1997 | — | 98 (21) |
| GVHD prophylaxis | 452 | — |
| CsA ± others (not MTX) | — | 93 (21) |
| CsA + MTX ± others | — | 286 (63) |
| MTX ± others (not CsA) | — | 8 (2) |
| T-depletion ± others | — | 58 (13) |
| Others/none | — | 7 (1) |
Bu indicates busulfan; Cy, cyclophosphamide; TLI, total lymphoid.